Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for SGLT2 treatments for diabetes. A potential third competitor from Eli Lilly and Boehringer Ingelheim, empagliflozin, failed to win FDA approval, thanks to problems at a Boehringer manufacturing plant.
written on 05.03.2014
In SGLT2 diabetes fight, Lilly's empagliflozin loss is J&J and AstraZeneca's gain
